

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 09/786,481 03/05/2001 Frank Hulstaert 11362.0034.P 8708 7590 12/14/2004 EXAMINER Patricia A Kammerer NICHOLS, CHRISTOPHER J Howrey Simon Arnold & White 750 Bering Drive ART UNIT PAPER NUMBER Houston, TX 77057-2198 1647

DATE MAILED: 12/14/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
Office Action Summary	09/786,481	HULSTAERT ET AL.
	Examiner	Art Unit
	Christopher J Nichols, Ph.D.	1647
The MAILING DATE of this communication Period for Reply	appears on the cover sheet with t	he correspondence address
A SHORTENED STATUTORY PERIOD FOR RETHE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFI after SIX (6) MONTHS from the mailing date of this communication - If the period for reply specified above is less than thirty (30) days, a - If NO period for reply specified above, the maximum statutory period for reply within the set or extended period for reply will, by st Any reply received by the Office later than three months after the mearned patent term adjustment. See 37 CFR 1.704(b).	DN. R 1.136(a). In no event, however, may a reply low reply within the statutory minimum of thirty (30 reply within the statutory minimum of thirty (30 monTHS atlute. cause the application to become ABAND atlute. cause the application to become ABAND	be timely filed) days will be considered timely. from the mailing date of this communication. ONED (35 U.S.C. & 133)
Status		
1)⊠ Responsive to communication(s) filed on 0	4 August 2003	
	This action is non-final.	
3) Since this application is in condition for allo closed in accordance with the practice und	wance except for formal matters,	
Disposition of Claims		
4) ☐ Claim(s) <u>1,5,8,11 and 18-20</u> is/are pending 4a) Of the above claim(s) is/are withen 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) <u>1,5,8,11 and 18-20</u> is/are rejected 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) <u>1,5,8,11 and 18-20</u> are subject to	drawn from consideration.	ment.
Application Papers		
 9) ☐ The specification is objected to by the Exam 10) ☑ The drawing(s) filed on 12 March 2003 is/ar Applicant may not request that any objection to a Replacement drawing sheet(s) including the con 11) ☐ The oath or declaration is objected to by the 	re: a) accepted or b) objected or b) objected the drawing(s) be held in abeyance. rection is required if the drawing(s) is	See 37 CFR 1.85(a). s objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for fore a) □ All b) □ Some * c) □ None of: 1. □ Certified copies of the priority docume 2. □ Certified copies of the priority docume 3. □ Copies of the certified copies of the p application from the International Bur * See the attached detailed Office action for a	ents have been received. ents have been received in Applic priority documents have been rece eau (PCT Rule 17.2(a)).	cation No eived in this National Stage
Attachment(s)	,, □ , , , , , ,	(07.5 4.6)
I) ⊠ Notice of References Cited (PTO-892) 2) ☑ Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) ∐ Interview Summ Paper No(s)/Mai	
B) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/Paper No(s)/Mail Date		al Patent Application (PTO-152)

Art Unit: 1647

DETAILED ACTION

Status of Application, Amendments, and/or Claims

- 1. The Finality of the Rejection mailed 2 September 2003 is hereby withdrawn to allow entry of new rejections based on a new reference. Prosecution on the merits is hereby reopened.
- 2. The Request for Correction of Inventorship under 37 C.F.R. 1.48(a) filed 14 October 2004 has been received and entered. It is hereby GRANTED by the Examiner. The Inventorship of the instant application is now: Frank Hulstaert, Eugeen Vanmechelen, Hugo Vanderstichele, André Van de Voorde, and Stefann Van Gool.
- 3. The Oath/Declaration filed 14 October 2004 has been received and entered in full.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- 4. Claims 1, 5, 8, 11, 18, 19, and 20 are rejected under 35 U.S.C. 102(e) as being anticipated by US 6,797,478 B1 (28 September 2004) Zemlan & Campbell.
- 5. US '478 teaches a method of measuring the level of tau in cerebrospinal fluid (CSF) to determine the presence and/or severity of central nervous system (CNS injury) including but not limited to cerebral infract, cerebral hypoxic injury, cerebral vascular accidents, and/or central

Application/Control Number: 09/786,481

Art Unit: 1647

Page 3

nervous system tumors thus meeting the limitations of claims 1 and 18 (Col. 3-5). As claimed

"anoxia" and "ischemia" fall into the rubric of "cerebral vascular accidents" thus meeting the

limitations of claims 1 and 18. US '478 also teaches that tau includes any or all of the six non-

cleaved isoforms of tau as well as cleaved forms thus meeting the limitations of claims 1 and 18

(Col. 4-5). US '478 also teaches calibrating the level of tau in CSF based on patients without

axonal degeneration versus patients with axonal degeneration (CNS injury) thus meeting the

limitations of claims 1 and 18 (Col. 5).

6. Also the causative agents and/or events of said anoxia and ischemia are also anticipated

by US '478 which teaches practicing the method for primary hemorrhages including cerebral

hemorrhage and arterial occlusion which includes thrombosis thus meeting the limitations of

claims 8 and 19 (Col. 3). US '478 also teaches practicing the method above to "ascertain or

predict clinical outcome following such trauma" thus meeting the limitations of claims 11 and 20

(Col. 3).

Summary

7. No claims are allowed.

SHARON L. TURNER, PH.D. PATENT EXAMINER

10 04

Art Unit: 1647

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Christopher James Nichols**, **Ph.D.** whose telephone number is **(571) 272-0889**. The examiner can normally be reached on Monday through Friday, 8:00 AM to 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, **Brenda Brumback** can be reached on **(571) 272-0961**.

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

CJN

December 9, 2004

SHAPON EXAMINER

12-10-04